Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Complement C3a/C3aR and C5a/C5aR deposits accelerate the progression of advanced IgA nephropathy to end-stage renal disease.

Ying Wang | Shunlai Shang | Shimin Jiang | Guming Zou | Hongmei Gao | Wenge Li
Clinical and experimental medicine | 2024

IgA nephropathy (IgAN) is still one of the leading causes of end-stage kidney disease (ESRD), and complement system activation is a key to the pathogenesis of IgAN. The role of complement C3a/C3aR and C5a/C5aR in late stage of IgAN remains unknown. Renal specimens of 75 IgAN patients at the stage 4 CKD were stained using immunofluorescence and immunohistochemistry. The primary outcome was a composite of end-stage renal disease (ESRD) and death. Associations of complement components with baseline clinicopathological characteristics and outcomes were assessed using multivariable Cox regression and Spearman analyses. During a median follow-up of 15.0 months, 27 patients progressed to ESRD and none died. Lower eGFR [hazards ratio (HR), 0.827, 95% confidence interval (CI), 0.732-0.935; P = 0.002] and glomerular C3 deposition (HR, 3.179, 95% CI, 1.079-9.363; P = 0.036) were predictive of time to ESRD in stage 4 CKD IgAN. Higher expression of C3a (P = 0.010), C3aR (P = 0.005), C5a (P = 0.015), and C5aR (P < 0.001) was identified in ESRD group than in non-ESRD group. Glomerular C3a/C3aR and C5a/C5aR deposits were both correlated with a lower baseline eGFR, higher baseline 24 h-urinary protein (24 h-UP) and faster decline of eGFR. Besides, C3a and C5a deposits were found in patients with high S (S1) and T (T1/2) scores, respectively. Complement C3a/C3aR and C5a/C5aR in IgAN patients with stage 4 CKD may portend a faster deterioration of kidney function.

Pubmed ID: 38951265

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: China Postdoctoral Science Foundation,
    Id: 2023M733986, 2023T160741
  • Agency: China Postdoctoral Science Foundation,
    Id: 2023M733986, 2023T160741
  • Agency: China Postdoctoral Science Foundation,
    Id: 2023M733986, 2023T160741
  • Agency: China Postdoctoral Science Foundation,
    Id: 2023M733986, 2023T160741
  • Agency: China Postdoctoral Science Foundation,
    Id: 2023M733986, 2023T160741
  • Agency: China Postdoctoral Science Foundation,
    Id: 2023M733986, 2023T160741
  • Agency: the cross-sectional project of China-Japan Friendship Hospital,
    Id: 2023-HX-JC-10
  • Agency: the cross-sectional project of China-Japan Friendship Hospital,
    Id: 2023-HX-JC-10
  • Agency: the cross-sectional project of China-Japan Friendship Hospital,
    Id: 2023-HX-JC-10
  • Agency: the cross-sectional project of China-Japan Friendship Hospital,
    Id: 2023-HX-JC-10
  • Agency: the cross-sectional project of China-Japan Friendship Hospital,
    Id: 2023-HX-JC-10
  • Agency: the cross-sectional project of China-Japan Friendship Hospital,
    Id: 2023-HX-JC-10
  • Agency: International Association of Chinese Nephrologists Research Grant,
    Id: IACNRG-01
  • Agency: International Association of Chinese Nephrologists Research Grant,
    Id: IACNRG-01
  • Agency: International Association of Chinese Nephrologists Research Grant,
    Id: IACNRG-01
  • Agency: International Association of Chinese Nephrologists Research Grant,
    Id: IACNRG-01
  • Agency: International Association of Chinese Nephrologists Research Grant,
    Id: IACNRG-01
  • Agency: International Association of Chinese Nephrologists Research Grant,
    Id: IACNRG-01

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Abcam (tool)

RRID:SCR_012931

A commercial antibody supplier which supplies primary and secondary antibodies, biochemicals, proteins, peptides, lysates, immunoassays and other kits.

View all literature mentions